Temozolomide therapy for aggressive pituitary tumours – current understanding and future perspectives
(2020) In Reviews in Endocrine and Metabolic Disorders 21(2). p.263-276- Abstract
The use of temozolomide (TMZ) for the management of aggressive pituitary tumours (APT) has revolutionised clinical practice in this field with significantly improved clinical outcomes and long-term survival. Its use is now well established however a large number of patients do not respond to treatment and recurrence after cessation of TMZ is common. A number of challenges remain for clinicians such as appropriate patient selection, treatment duration and the role of combination therapy. This review will examine the use of TMZ to treat APT including mechanism of action, treatment regimen and duration; biomarkers predicting response to treatment and patient selection; and current evidence for administration of TMZ in combination with... (More)
The use of temozolomide (TMZ) for the management of aggressive pituitary tumours (APT) has revolutionised clinical practice in this field with significantly improved clinical outcomes and long-term survival. Its use is now well established however a large number of patients do not respond to treatment and recurrence after cessation of TMZ is common. A number of challenges remain for clinicians such as appropriate patient selection, treatment duration and the role of combination therapy. This review will examine the use of TMZ to treat APT including mechanism of action, treatment regimen and duration; biomarkers predicting response to treatment and patient selection; and current evidence for administration of TMZ in combination with other agents.
(Less)
- author
- Burman, Pia LU ; Lamb, Lydia and McCormack, Ann
- organization
- publishing date
- 2020-03-09
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Aggressive pituitary tumour, Biomarker, Combination therapy, Pituitary carcinoma, Temozolomide
- in
- Reviews in Endocrine and Metabolic Disorders
- volume
- 21
- issue
- 2
- pages
- 14 pages
- publisher
- Springer
- external identifiers
-
- scopus:85081671933
- pmid:32147777
- ISSN
- 1389-9155
- DOI
- 10.1007/s11154-020-09551-y
- language
- English
- LU publication?
- yes
- id
- da7ea206-96fc-4cf1-ab9e-3c3b4d2b59c1
- date added to LUP
- 2020-04-07 17:17:37
- date last changed
- 2024-06-12 11:46:14
@article{da7ea206-96fc-4cf1-ab9e-3c3b4d2b59c1,
abstract = {{<p>The use of temozolomide (TMZ) for the management of aggressive pituitary tumours (APT) has revolutionised clinical practice in this field with significantly improved clinical outcomes and long-term survival. Its use is now well established however a large number of patients do not respond to treatment and recurrence after cessation of TMZ is common. A number of challenges remain for clinicians such as appropriate patient selection, treatment duration and the role of combination therapy. This review will examine the use of TMZ to treat APT including mechanism of action, treatment regimen and duration; biomarkers predicting response to treatment and patient selection; and current evidence for administration of TMZ in combination with other agents.</p>}},
author = {{Burman, Pia and Lamb, Lydia and McCormack, Ann}},
issn = {{1389-9155}},
keywords = {{Aggressive pituitary tumour; Biomarker; Combination therapy; Pituitary carcinoma; Temozolomide}},
language = {{eng}},
month = {{03}},
number = {{2}},
pages = {{263--276}},
publisher = {{Springer}},
series = {{Reviews in Endocrine and Metabolic Disorders}},
title = {{Temozolomide therapy for aggressive pituitary tumours – current understanding and future perspectives}},
url = {{http://dx.doi.org/10.1007/s11154-020-09551-y}},
doi = {{10.1007/s11154-020-09551-y}},
volume = {{21}},
year = {{2020}},
}